A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2012
At a glance
- Drugs Milnacipran (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Acronyms MyFi
- Sponsors Forest Laboratories
- 23 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov record.
- 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 02 May 2012 Planned end date changed from 1 May 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.